Inclusion Criteria:

          -  Provide a signed and dated informed consent form prior to initiation of study-specific
             procedures.

          -  Patients with the indicated advanced or metastatic solid tumor as follows:

               1. NSCLC who are planned for or have received no more than 1 cycle of systemic
                  treatment with cytotoxic, platinum-based chemotherapy (note: patients who have
                  received anti-PD-(L)1 monotherapy are eligible)

               2. GEA who are planned for or have received no more than 1 cycle of systemic
                  treatment with cytotoxic, platinum-based chemotherapy

               3. mUC who are planned for or have received no more than 1 cycle of systemic
                  treatment with cytotoxic, platinum-based chemotherapy

               4. CRC-MSS who are receiving first line systemic therapy or who are planned for or
                  have received no more than 1 cycle of second line systemic therapy including a
                  fluoropyrimidine and oxaliplatin or irinotecan

          -  18 years of age or older

          -  ECOG Performance Status 0 or 1

          -  Lesion amenable to biopsy

          -  Measurable disease according to RECIST v1.1

          -  Have adequate organ function, as measured by laboratory values (criteria listed in
             protocol)

        Exclusion Criteria:

          -  Tumors with genetic characteristics as follows:

               1. For NSCLC, patients with a known genetic driver alteration in EGFR, ALK, ROS1,
                  RET, or TRK

               2. For CRC and GEA, patients with known MSI-high disease based on institutional
                  standard

               3. For CRC, patients with a known BRAF V600E mutation or patients with peritoneal
                  carcinomatosis and for GEA, patients with peritoneal carcinomatosis as their only
                  evidence of disease

          -  Patients with known central nervous system (CNS) metastases and/or carcinomatous
             meningitis

          -  Known exposure to chimpanzee adenovirus or any history of anaphylaxis in reaction to a
             vaccination or allergy or hypersensitivity to study drug components

          -  Bleeding disorder (eg., factor deficiency, coagulopathy) or history of significant
             bruising or bleeding following IM injections or blood draws

        Complete inclusion and exclusion criteria are listed in the clinical study protocol.